Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUS NASDAQ:CSTL NYSE:PACS NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$109.69+1.2%$112.52$88.96▼$136.72$2.00B0.81165,970 shs138,793 shsCSTLCastle Biosciences$17.39-6.9%$18.09$15.45▼$35.84$539.34M1.1419,998 shs482,351 shsPACSPACS Group$12.36+0.0%$11.45$8.28▼$43.92$1.88B0.92809,313 shs565,654 shsVCYTVeracyte$24.22-3.8%$27.27$19.73▼$47.32$1.97B2.07917,433 shs820,850 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare+1.15%-2.24%-3.81%+8.34%-10.13%CSTLCastle Biosciences-6.91%-12.35%-6.20%-19.15%-10.41%PACSPACS Group-0.12%-3.40%+0.81%+33.78%-62.76%VCYTVeracyte-3.77%-11.99%-9.49%-22.22%-4.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADUSAddus HomeCare4.9641 of 5 stars3.64.00.05.03.42.53.1CSTLCastle Biosciences2.2307 of 5 stars3.52.00.00.02.32.50.0PACSPACS Group2.7746 of 5 stars3.41.00.00.02.20.01.9VCYTVeracyte3.5566 of 5 stars3.41.00.04.32.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 3.25Buy$142.5729.98% UpsideCSTLCastle Biosciences 3.00Buy$37.00112.77% UpsidePACSPACS Group 2.86Moderate Buy$34.29177.50% UpsideVCYTVeracyte 2.70Moderate Buy$40.9068.87% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, VCYT, ADUS, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.006/20/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.006/10/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$133.005/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/8/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$129.00 ➝ $133.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/22/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.00 ➝ $150.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.15B1.75$5.45 per share20.12$53.52 per share2.05CSTLCastle Biosciences$332.07M1.51$0.92 per share18.99$16.28 per share1.07PACSPACS Group$3.11B0.61N/AN/AN/A∞VCYTVeracyte$445.76M4.26$1.00 per share24.27$15.17 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$73.60M$4.4324.7620.461.546.52%9.23%6.96%8/4/2025 (Estimated)CSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)PACSPACS Group$112.87MN/A0.006.94N/AN/AN/AN/A8/11/2025 (Estimated)VCYTVeracyte$24.14M$0.4159.0733.64N/A7.13%6.14%5.60%8/5/2025 (Estimated)Latest CSTL, VCYT, ADUS, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q3 2024PACSPACS Group$0.45N/AN/AN/AN/AN/A8/5/2025Q2 2025VCYTVeracyte$0.31N/AN/AN/A$120.90 millionN/A8/4/2025Q2 2025ADUSAddus HomeCare$1.45N/AN/AN/A$345.71 millionN/A8/4/2025Q2 2025CSTLCastle Biosciences-$0.44N/AN/AN/A$71.53 millionN/A5/5/2025Q1 2025ADUSAddus HomeCare$1.33$1.42+$0.09$1.16$341.66 million$337.71 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.201.741.74CSTLCastle Biosciences0.029.379.19PACSPACS GroupN/AN/AN/AVCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%CSTLCastle Biosciences92.60%PACSPACS GroupN/AVCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.60%CSTLCastle Biosciences6.50%PACSPACS GroupN/AVCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare49,70318.40 million17.55 millionOptionableCSTLCastle Biosciences54028.87 million27.00 millionOptionablePACSPACS Group32,433152.40 millionN/AOptionableVCYTVeracyte79078.32 million77.22 millionOptionableCSTL, VCYT, ADUS, and PACS HeadlinesRecent News About These CompaniesVeracyte to Release Second Quarter 2025 Financial Results on August 6, 2025July 17 at 5:30 PM | businesswire.comSegall Bryant & Hamill LLC Has $13.90 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)July 17 at 6:51 AM | marketbeat.comShould You Continue to Hold Veracyte Stock in Your Portfolio Now?July 16 at 9:41 AM | zacks.comNew York State Common Retirement Fund Sells 118,642 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 16 at 4:33 AM | marketbeat.comRice Hall James & Associates LLC Acquires 19,843 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 15 at 5:45 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of TexasJuly 14, 2025 | marketbeat.comVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - MorningstarJuly 10, 2025 | morningstar.comMVeracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025July 9, 2025 | tmcnet.comWealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)July 6, 2025 | marketbeat.comVeracyte, Inc. (VCYT) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 1, 2025 | marketbeat.comWall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to HoldJune 28, 2025 | marketbeat.comAMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)June 26, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from AnalystsJune 23, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comGAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)June 19, 2025 | marketbeat.comCathie Wood’s ARK buys BWX stock, sells Adaptive BiotechJune 18, 2025 | investing.comVeracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved ProfitabilityJune 9, 2025 | msn.comCathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D SystemsJune 7, 2025 | benzinga.comInsider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)June 6, 2025 | gurufocus.comVeracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, VCYT, ADUS, and PACS Company DescriptionsAddus HomeCare NASDAQ:ADUS$109.69 +1.25 (+1.15%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$109.67 -0.02 (-0.02%) As of 07/17/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Castle Biosciences NASDAQ:CSTL$17.39 -1.29 (-6.91%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$17.82 +0.43 (+2.47%) As of 07/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.PACS Group NYSE:PACS$12.36 +0.01 (+0.04%) Closing price 07/17/2025 03:59 PM EasternExtended Trading$12.60 +0.24 (+1.98%) As of 07/17/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Veracyte NASDAQ:VCYT$24.22 -0.95 (-3.77%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$24.68 +0.46 (+1.88%) As of 07/17/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
